Did you know our Sarcoma Support Team can connect you with a trained volunteer who’s been impacted by sarcoma? Survivors & caregivers are available to talk by phone or email to share their experiences and tips. Learn more: https://t.co/YQvav2Ck5V

So proud to see @PeterHoseinMD presenting “Is Pancreas Subtyping Ready for Prime Time?” at #ASCO25 during the #PancreaticCancer panel. I’ve learned—and continue to learn—so much about oncology with him. What a privilege to have him at @SylvesterCancer

Please join me in the Trainee & Early Career Lounge Located in Hall C for specialized programming, complimentary refreshments, and a comfortable space to relax for Student, Resident, Fellow, and Early Career Oncologists. #ASCO25 @ASCO @SylvesterCancer

Honored to share insights on the challenges of #GIcancers and the ongoing efforts to improve patient outcomes. None of this would be possible without the dedication of our outstanding clinical and research team. Proud to be part of this mission! @rachnatshroff @UAZHemeOnc

🧐 New research on desmoid-type fibromatosis (DTF) highlights pegylated liposomal doxorubicin as an effective, well-tolerated treatment and explores a possible link between DTF and psychiatric conditions. Read more: https://t.co/tVxajPwYso #DesmoidFibromatosis #CancerResearch

Join us today!

@TumorBoardTues @SteveBialickDO @GinaDAmatoMD1 @CureSarcoma @Sarcoma_UK @BiachiTiago @MPishvaian @PriscilaBCMD @jacobadashek @HemOncFellows @stern_sydney @OncoKate @BRoseMDMPH @RenoHemonc @Liferaftgroup @JTrentMDPhD @KevinCalsina @IlanaSchlam @drsarahsam ALSO: July is Sarcoma Awareness Month! Help us raise awareness and encourage the use of biomarker-directed treatments to improve outcomes for people living with #sarcoma

Extremely grateful Mr. Horowitz for his extreme generosity and drive to help find the better treatments and maybe even the cure for solitary fibrous tumor #HSFTI (Horowitz Solitary Fibrous Tumor Initiative). Global collaborations have already started!

A robust 3D organoid bioprinting protocol and an imaging approach that facilitates single-organoid analysis of response to #cancer treatment. @soragnilab https://t.co/FsqcZlk6cP

Ecuador in the house @AndreaEspejoMD @BernabeCarolina 🇪🇨 Ecuador suena en #asco2023 #womeninoncology #miaminights

Amazing angiosarcoma data by Dr. Grilley-Olson 👏🏻 Cabo+nivo with responses in cutaneous and non-cutaneous AS ⁦#sarcoma #ASCO23

It was awesome to have the opportunity to share so many moments with this amazing #sarcoma experts 🤩☺️#ASCO2023 @JTrentMDPhD @Robertasanfili @GinaDAmatoMD1 @PriscilaBCMD

Combination chemo plus IO: DOX 75 mg/m2/d on D1 followed by DAC 400 mg/m2/d on D1 & 2, plus NIV 360 mg on D2 after DAC Q3W, followed by 1-year NIV maintenance is a feasible and well-tolerated in patients with #leiomyosarcoma #sarcoma #ASCO23 @OncoAlert

I feel honored to be a recipient of the #ASCO2023 Conquer Cancer - Howard Lessner, MD, Endowed Merit Award supported by Dr. Michael and Deborah Troner. Thank you for supporting young investigators and women in oncology #conquercancer #latinosinoncology #weconquercancer -#usfq

Cathy, thanks for leading (and completing) this impactful trial!

Congratulations to Dr. Priscila Barreto Coelho (@PriscilaBCMD), who was awarded the 2023 #BreastCancer #Research Foundation Young Investigator Award at #ASCO23. 🎉

Rein in Sarcoma Circle of Support is a community to post your sarcoma experience, ask questions, share resources, and find support from those who “have been there”. Please join our closed Facebook page to connect with others impacted by sarcoma. https://t.co/JR7UVhxfXm

Congratulations @PriscilaBCMD @SylvesterCancer on your @ASCO #YIA @GinaDAmatoMD1 @EmilyJonczak @SteveBialickDO @OncoAlert @ConquerCancerFd

Excited for the upcoming @reininsarcoma #Sarcoma Research Symposium happening this Friday 3/31. Virtual option for joining available Awesome research from the @UMNews @MayoClinic will be presented. I invite anyone interested in sarcoma research to join. @ExDirRIS @Cancerhunter1

RCT in #desmoid fibromatosis with nirogacestat. Patients on active drug also had a significant improved HRQoL vs placebo. Pain in desmoid patients can affect their HRQoL to a great extent and having a drug that can reduce pain is a big step forward.